Tracking serious influenza, COVID-19, and other respiratory infections in working-age Indian adults
Official title: RFA-IP-22-001 - Burden and sequelae of influenza, SARS-CoV-2 and other respiratory viruses associated Severe Acute Respiratory Infections among Indian adult population aged 18-60yrs
Funded at All-India Institute of Medical Sciences · NIH-11137548 · Data updated 2026-11-12
This project follows adults aged 18–60 in India who get severe respiratory infections to find out how often they happen, what long-term problems and costs result, and how well vaccines protect against serious illness.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | All-India Institute of Medical Sciences NIH-funded |
| Lab location | 1 site (New Delhi, India) |
| Project start | September 30, 2023 |
| Project end | September 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $400,000 |
| NIH project number | 5U01IP001171-03 |
| Project ID | NIH-11137548 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults aged 18–60 in India who are hospitalized with severe acute respiratory infections or who agree to join follow-up after such an illness are the best candidates.
✕Less likely to help
Children, people over 60, those without respiratory illness, or people living outside participating regions of India are unlikely to be enrolled or directly benefit from this project.
What this research studies
Researchers at major public hospitals across India will enroll adults hospitalized with severe acute respiratory infections into a common registry and collect respiratory samples to identify the viruses. Enrolled patients will be followed over time to document recovery, any longer-term health effects, and the chance of getting infected again. The project will record treatment costs and ask about vaccine use and hesitancy, then compare outcomes by vaccination status to estimate protection. The network will also train health professionals and share findings with policymakers to improve prevention and care.
Why it matters
Potential benefit: If successful, this work could guide policies to prevent severe infections, improve vaccine use, and reduce long-term health and economic impacts for working-age adults in India.
How similar studies have gone: Hospital-based surveillance and vaccine-effectiveness efforts — including earlier work at AIIMS — have previously informed public health actions, and this project expands that approach to more sites.
Where this research is happening
-
All-India Institute of Medical Sciences
New Delhi, India Active
Researchers
- Principal investigator: Krishnan, Anand — All-India Institute of Medical Sciences
- Study coordinator: Krishnan, Anand
Related research
Other NIH-funded projects on the same topics.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Burden and consequences of influenza, SARS-CoV-2 and other respiratory viruses among Indian adults
This grant aims to study how flu and COVID-19 and related respiratory infections affect Indian adults 18–60, including costs, outcomes, and vaccine uptake to inform health policy.
-
Leptin and fat cells: how obesity may worsen lung infections like COVID-19 and flu
A study explores how fat tissue and the leptin pathway might change the body's first lung defenses during respiratory infections in people who are obese or have diabetes.
-
Vaccine effectiveness in preventing respiratory illness in Washington state (2022–2027)
This project tests how well vaccines against flu, COVID-19, and other respiratory viruses protect people in Washington state from getting acutely ill.
-
Understanding flu and COVID-19 vaccine responses in adults
A Stanford-led effort studies how the flu and COVID-19 vaccines work in adults and how to make them work better for people, especially those with higher risk from underlying health conditions.
-
How flu, COVID-19, and other respiratory vaccines protect people in Washington from sudden respiratory illness
This project checks how well seasonal flu, COVID-19, and other respiratory vaccines prevent short-term respiratory illnesses in people living in Washington state.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.